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The  thyroid  hormones  triiodothyronine  and  thyroxine  act  on  almost  every  cell  and  organ
in  the  body,  with  intense  effects  on  the  cardiovascular  system.  The  heart  is  a  major  tar-
get  organ  for  thyroid  hormone  action  and  marked  changes  occur  in  cardiac  function  in
patients  with  hypothyroidism  or  hyperthyroidism.  Although  thyroxine  is  the  major  thy-
roid  secretion  product,  triiodothyronine  is  responsible  for  most  of  the  biological  effects
ascribed  to  thyroid  hormones,  including  the  negative-feedback  system  for  secretion  of
thyrotropin-releasing  hormone  and  thyroid-stimulating  hormone  by  the  hypothalamus  and
pituitary,  respectively.  Among  the  different  tissues,  triiodothyronine  has  pivotal  effects  on
the  cardiovascular  system,  acting  as  an  important  regulator  of  cardiovascular  haemody-
namics  through  its  direct  action  on  cardiac  myocytes,  vascular  smooth  muscle  cells  (VSMCs)Hormones
thyroïdiennes  ;
Monoxyde  d’azote  ;
NO  synthase  ;
Endothélium
and  endothelium  [1,2]. Thyroid  disease  is  quite  common.  Current  estimates  suggest  that
it  affects  as  many  as  9  to  15%  of  the  adult  female  population  and  a  smaller  percentage
of  adult  men.  This  sex-speciﬁc  prevalence  almost  certainly  results  from  the  autoimmune
mechanism  underlying  the  most  common  forms  of  thyroid  disease  [3].
Abbreviations: ADMA, asymmetrical dimethyl arginine; Akt, protein kinase B; LDL, low-density lipoprotein; NO, nitric oxide; NOS, nitric
oxide synthase; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase; PI3K,
phosphatidylinositol 3-kinase; VSMC, vascular smooth muscle cells.
∗ Corresponding author.
E-mail address: luc.rochette@u-bourgogne.fr (L. Rochette).
http://dx.doi.org/10.1016/j.acvd.2014.02.001
1875-2136/© 2014 Elsevier Masson SAS. All rights reserved.
2d
i
n
t
h
e
a
g
s
w
a
r
N
b
d
t
v
f
d
[
r
f
i
c
t
a
v
s
a
j
t
R
u
c
t
t
t
m
i
c
i
o
a
m
n
d
p
p
t
r
h
r
t
e
g
m
l
o
c
t
I
t
T
t
p
t
h
T
t
t
m
t
c
b
i
m
e
t
a
c
o
p
w
[
N
a
N
e
n
I
N
r
c
c
c
c
s
N
f
t
i
c
r
d
b
o
o
[
i
i
c
m
r
remain  unclear.  Thyroid  hormone-induced  rapid  vascular
relaxation  is  mediated  by  VSMC-derived  NO  production  and08  
The  mechanism  of  action  of  thyroid  hormones  has  been
escribed  as  beginning  in  the  cell  nucleus  and  requir-
ng  the  participation  of  speciﬁc  receptor  proteins  in  the
uclear  compartment.  The  classic  genomic  action  of  triiodo-
hyronine  occurs  through  its  binding  to  the  nuclear  thyroid
ormone  receptor,  which  binds  to  thyroid  hormone  response
lements  in  the  promoter  regions  of  target  genes,  thereby
ctivating  or  repressing  their  transcription  [4]. The  thyroid
land,  in  response  to  thyroid-stimulating  hormone,  synthe-
izes  and  releases  thyroid  hormones  (mostly  as  thyroxine
ith  <  5%  as  triiodothyronine).  The  majority  of  biologically
ctive  triiodothyronine  derives  from  the  conversion  of  thy-
oxine  by  type  I  or  type  II  5′-deiodinase  in  peripheral  tissues.
ormally,  the  heart  relies  on  circulating  triiodothyronine
ecause  no  signiﬁcant  cardiac  myocyte  intracellular  deio-
inase  activity  occurs  [5].  Among  the  different  tissues,
riiodothyronine  has  pivotal  effects  on  the  heart  and  cardio-
ascular  system,  acting  as  an  important  regulator  of  cardiac
unction  and  cardiovascular  haemodynamics  through  its
irect  action  on  cardiac  myocytes,  VSMCs  and  endothelium
6].  The  increase  in  cardiac  output  observed  in  hyperthy-
oidism  results  from  a  combination  of  increased  cardiac
unction  (inotropic  and  chronotropic  effects)  and  changes
n  cardiovascular  haemodynamics  (lowered  systemic  vas-
ular  resistance  and  increased  blood  volume),  suggesting
hat  reduced  vascular  resistance  could  be  secondary  to
lterations  in  the  vascular  control  mechanisms  that  favour
asodilatation  [7].  The  precise  mechanism  of  the  decline  in
ystemic  vascular  resistance  in  hyperthyroidism  is  not  known
nd  there  are  some  contradictory  results  relating  to  this  sub-
ect.  Thyroid  hormones  affect  cardiac  myocytes  as  well  as
he  smooth  muscle  and  endothelial  cells  of  the  vascular  wall.
elatively  little  is  known  about  the  mechanisms  that  reg-
late  the  interaction  of  triiodothyronine  with  endothelial
ells.
It  has  been  suggested  that  hyperthyroidism  is  similar
o  a  hyperadrenergic  state;  however,  no  evidence  suggests
hat  triiodothyronine  excess  enhances  the  sensitivity  of
he  heart  to  adrenergic  stimulation  [8].  Triiodothyronine-
ediated  inhibition/phosphorylation  of  phospholamban
nvolves  intracellular  kinase  pathways  shared  by  cate-
holamine  signal  transduction;  this  underlines  the  similar-
ties  between  triiodothyronine  and  catecholamine  effects
n  heart  and  vessels  [9].  The  classic  genomic  actions
re  dependent  on  interaction  with  nuclear  receptors  to
odulate  cardiac  myocyte  gene  expression.  Triiodothyro-
ine  enters  the  cell  membrane  by  simple  diffusion,  as
escribed  for  steroidal  hormones,  or  via  speciﬁc  trans-
ort  proteins,  such  as  an  energy-dependent  carrier  that
artially  depends  on  the  sodium  gradient.  In  the  nucleus,
riiodothyronine  interacts  with  the  nuclear  thyroid  hormone
eceptor.  The  mechanism  of  action  of  thyroid  hormones
as  been  described  as  starting  in  the  cell  nucleus  and
equiring  the  participation  of  speciﬁc  receptor  proteins  in
he  nuclear  compartment.  However,  there  is  now  growing
vidence  for  triiodothyronine-  and  thyroxine-triggered  non-
enomic  pathways,  resulting  from  their  binding  to  plasma
embrane,  cytoplasm  or  mitochondrial  receptors,  which
eads  to  rapid  regulation  of  cardiac  functions.  Some  actions
f  thyroid  hormones  are  now  assumed  to  involve  extranu-
lear  mechanisms  in  a  variety  of  cells;  these  are  initiated  at
he  plasma  membrane  receptor  for  iodothyronines  [4]. iL.  Osmak-Tizon  et  al.
mportance of the non-genomic actions of
hyroid hormones
he  mechanisms  of  several  of  the  non-genomic  actions  of
hyroid  hormone  have  now  been  elucidated,  at  least  in
art;  they  depend  upon  cellular  signal  transduction  sys-
ems  and  either  novel  cell  surface  receptors  for  thyroid
ormone  or  the  extranuclear  thyroid  hormone  receptors
R  and  TR  [10].  The  non-genomic  actions  of  triiodo-
hyronine  in  the  myocardium  are  envisaged  to  affect  the
ransporter  localized  at  the  plasma  membrane  and  the
echanisms  associated  with  nitric  oxide  (NO)  metabolism,
hrough  mechanisms  that  involve  distinct  signalling  cas-
ades.  It  is  assumed  that  these  actions  involve  extranuclear
inding  sites  in  several  compartments  of  the  cell,  includ-
ng  the  plasma  membrane,  cytoskeleton,  cytoplasm  and
itochondria.  Unlike  the  nuclear  effects,  the  extranuclear
ffects  are  independent  of  thyroid  hormone  nuclear  recep-
ors,  may  occur  within  a  short  time  (seconds  to  minutes)
nd  may  be  mediated  by  signal-transducing  pathways.  A
ell  surface  receptor  for  iodothyronines  has  been  described
n  a  structural  protein  of  the  plasma  membrane;  this
rotein  is  integrin  V3,  a  heterodimer  that  interacts
ith  a substantial  number  of  extracellular  matrix  proteins
11].
itric oxide synthases: targets for the
ctions of thyroid hormones?
O  can  be  generated  by  three  different  isoforms  of  the
nzyme  NO  synthase  (NOS).  The  isozymes  are  referred  to  as
euronal  NOS  (nNOS  or  NOS  I),  inducible  NOS  (iNOS  or  NOS
I)  and  endothelial  NOS  (eNOS  or  NOS  III).  All  isoforms  of
OS  use  l-arginine  as  substrate  and  molecular  oxygen  and
educed  nicotinamide-adenine-dinucleotide  phosphate  as
o-substrates.  Flavin  adenine  dinucleotide,  ﬂavin  mononu-
leotide  and  (6R)-5,6,7,8-tetrahydro-l-biopterin  (BH4)  are
o-factors  of  all  isozymes  [12].  The  endothelium  plays  a
rucial  role  in  the  regulation  of  cardiovascular  homeosta-
is,  through  the  release  of  vasoactive  compounds  such  as
O,  prostacyclin  and  endothelium-derived  hyperpolarizing
actor.  eNOS  has  been  reported  to  be  under  the  con-
rol  of  caveolin,  the  structural  protein  of  caveolae.  eNOS
s  reversibly  targeted  to  signal-transducing  plasmalemmal
aveolae,  where  the  enzyme  interacts  with  a number  of
egulatory  proteins,  many  of  which  are  modiﬁed  in  car-
iovascular  disease  states  [13]. Recently,  NO  production
y  VSMCs  was  identiﬁed  as  an  important  mechanism  for
verproduction  of  NO  in  the  vascular  wall  and  might  be
f  importance  for  the  local  control  of  vascular  function
14].
Substrate  and  co-factor  availability  play  important  roles
n  regulating  NOS  activity,  not  only  by  limiting  enzyme  activ-
ty  but  also  by  inﬂuencing  the  coupling  of  NOS  with  its
o-factors.  Other  potential  regulators  of  NOS,  such  as  hor-
ones,  may  also  be  important.  Thyroid  hormone  rapidly
elaxes  VSMCs,  but  the  mechanisms  involved  in  this  effects  associated  with  the  phosphatidylinositol  3-kinase/protein
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triiodothyronine-induced  NO  production.  Akt  phosphoryla-
tion  has  been  shown  to  induce  concomitant  activation  of
transcription  factor  nuclear  factor-B,  a  pivotal  regulatorNon-genomic  actions  of  thyroid  hormones:  Molecular  aspect
kinase  B  (PI3K/Akt)  signalling  pathway.  Triiodothyronine
signiﬁcantly  increased  the  expression  of  three  NOS  iso-
forms  in  endothelial  and  muscular  cells,  but  only  nNOS
and  iNOS  played  a  signiﬁcant  role  in  NO  production  by
VSMCs  [15].  New  data  have  identiﬁed  only  nNOS  and  eNOS
as  targets  for  the  actions  of  thyroid  hormone.  There  is
evidence  that  triiodothyronine  exerts  a  direct  vasodilator
effect  through  different  endothelial  mechanisms  [10]  and
new  studies  suggest  that  the  smooth  muscle  layer  also  con-
stitutes  an  important  target  for  the  vasorelaxant  effects  of
triiodothyronine.  Given  that  the  amount  of  NO  produced
by  iNOS  is  greater  than  that  produced  by  eNOS  and  nNOS,
it  is  conceivable  that  iNOS  makes  a  greater  contribution
than  nNOS  to  triiodothyronine-induced  NO  production  in
VSMCs.
In  addition,  increased  vascular  NO  production  has  been
reported  in  rats  in  hyperthyroid  states  [16].  Although  this
response  has  been  associated  with  augmented  endothelium-
dependent  vasodilation,  greater  nNOS  and  eNOS  expression
was  found  in  the  VSMCs,  suggesting  that  changes  in  NO  pro-
duction  occur  not  only  in  the  endothelial  cells  but  also  in
other  layers  of  the  vascular  wall,  contributing  to  the  aug-
mented  vasodilation.  After  thyroid  hormone  replacement
in  patients  with  subclinical  hypothyroidism,  a  signiﬁcant
improvement  in  acetylcholine-induced  vasodilatation  was
observed  (along  with  an  unchanged  response  to  sodium
nitroprusside)  [17].
An  interesting  study  aimed  to  evaluate  plasma  small
dense  low-density  lipoprotein  (LDL),  l-arginine  and  dimethy-
larginine  concentrations  and  their  relationship  to  NO
production  in  patients  with  subclinical  hypothyroidism
before  and  after  thyroxine  replacement  therapy  and  com-
pared  with  control  group  values  [18].  Among  the  new
biochemical  risk  factors,  asymmetrical  dimethyl  arginine
(ADMA),  an  endogenous  inhibitor  of  NOS,  was  deﬁned  in
cardiovascular  risk  assessment  [12].  ADMA  and  l-arginine
concentrations  in  patients  with  subclinical  hypothyroidism
were  signiﬁcantly  higher  than  in  the  control  group  and  were
not  different  from  the  control  group  after  thyroid  hormone
replacement.  Exogenous  thyroid  hormone  appears  to  beneﬁt
endothelial  function  in  patients  with  subclinical  hypothy-
roidism  by  lowering  blood  ADMA  concentrations.
Recently,  a  study  investigated  the  effects  of  both  native
and  oxidized  LDL  on  triiodothyronine-mediated  Akt  phos-
phorylation  and  NO  and  cyclic  guanosine  monophosphate
production  in  human  endothelial  cells.  The  results  of  this
study  demonstrated  that  oxidized  LDL  may  contribute  to
a  blunting  of  the  non-genomic  action  of  triiodothyronine
and  impair  the  effect  of  triiodothyronine  on  NO  and  cyclic
guanosine  monophosphate  production  in  endothelial  cells.
These  data  suggest  that  oxidized  LDL,  apart  from  inducing
the  atherosclerotic  process,  may  also  promote  a  mecha-
nism  of  peripheral  resistance  to  triiodothyronine  [19]. It  is
also  important  to  remember  that,  in  certain  conditions,  thy-
roid  hormones  are  able  to  limit  the  oxidative  modiﬁcations
of  LDL  via  a  free  radical  scavenging  capability  [20]. The
results  of  these  studies  are  of  potential  clinical  relevance.
Endothelial  dysfunction,  resulting  from  a  reduction  in  NO
availability  and  LDL  oxidation,  is  a  common  event  in  car-
diovascular  disease,  and  thyroid  dysfunction  is  a  frequent
condition  that  confers  an  increased  risk  of  cardiovascular
complications. o209
elationship between adipocytokines,
hyroid hormones and bioavailable nitric
xide produced by endothelial cells
dipose  tissue  is  widely  considered  as  a  hormonally  active
ystem  with  metabolic  effects.  The  term  ‘‘adipocytokines’’
as  been  coined  to  designate  different  bioactive  substances
erived  from  adipose  tissue  that  modulate  several  functions
n  other  tissues.  Adipose  tissue  is  a  hormonally  active  system
hat  produces  and  releases  different  bioactive  substances.
diponectin  and  leptin  are  two  of  the  adipokines  released
rom  adipose  tissue  and  they  modulate  homeostasis,  lipid
nd  glucose  metabolism.  Plasma  adiponectin  concentra-
ions  are  correlated  negatively  with  adiposity  and  metabolic
yndrome.  The  interaction  between  leptin  and  thyroid  hor-
ones  is  not  straightforward.  Leptin  has  a  role  in  the
egulation  of  thyrotropin-releasing  hormone  gene  expres-
ion  and  thyroid-stimulating  hormone  directly  stimulates
eptin  secretion  by  human  adipose  tissue.  The  relationship
etween  adiponectin  and  thyroid  hormones  is  not  clearly
eﬁned  [21].
Leptin  has  an  NO-mediated  vasodilative  action,  which
s  associated  with  blood  pressure  reduction.  This  leptin-
nduced  endothelium-derived  relaxation  is  also  mediated  by
nhanced  endothelial  neuronal  NOS  production  [22]. Despite
his  vasodilative  effect,  leptin  was  shown  to  decrease
ioavailable  NO  produced  by  endothelial  cells  when  they
ere  exposed  to  this  adipokine;  this  is  thought  to  be
aused  by  increased  oxidative  stress  [23].  Hypoadiponecti-
aemia  has  also  been  associated  with  impaired  NO-mediated
ndothelium-dependent  vasodilation.  Adiponectin  binds  to
diponectin  receptors  1  and  2  and  triggers  a  cascade  that
eads  to  decreased  reactive  oxygen  species,  increased  NO
nd  decreased  adhesion  molecules  [24].  Adiponectin  has
een  shown  to  inhibit  the  generation  of  high  glucose-induced
eactive  oxygen  species  in  human  glomerular  mesangial
ells;  it  also  stimulates  eNOS  activity,  which  has  a  protective
ffect.  The  mechanism  partly  occurs  through  stimulation
f  the  adenosine  monophosphate-activated  protein  kinase-
ignalling  pathway  [25].
verview of non-nuclear pathways: direct
nd indirect
nlike  nuclear  effects,  extranuclear  effects  may  be
ediated  by  signal-transducing  pathways,  such  as  cyclic
denosine  monophosphate  and  protein  kinases.  Thyroid
ormones  affect  cellular  calcium  homeostasis  and  this
ffect  is  probably  due  to  a  non-genomic  action.  T2  (-3,5-
iiodo-L-thyronine)  and  triiodothyronine  exert  short-term
on-genomic  effects  on  intracellular  calcium  by  mod-
lating  plasma  membrane  and  mitochondrial  pathways
26]. Regarding  the  signalling  pathway  associated  with
he  non-genomic  action  of  thyroid  hormones,  it  has  also
een  suggested  that  the  PI3K/Akt  pathway  is  involved  inf  iNOS  expression.
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[10  
From  the  cell  surface  receptor,  the  thyroid  hormone  sig-
al  is  transduced.  There  is  a  triiodothyronine-speciﬁc  site
n  the  domain,  as  well  as  a  site  at  which  both  thyroxine
nd  triiodothyronine  may  act.  The  triiodothyronine-speciﬁc
ite  activates  PI3K,  thyroxine  being  unable  to  activate  PI3K.
he  consequences  of  this  action  of  triiodothyronine  include
ranscription  of  the  hypoxia-inducible  factor-1  (HIF1-)
ene,  activation  of  plasma  membrane  sodium  and  potas-
ium  adenosine  triphosphatase  and  its  insertion  in  the
lasma  membrane  [27].  Additionally,  these  mechanisms  may
e  affected  by  many  non-genomic  actions,  such  as  post-
ranslational  modiﬁcations,  by  local  bioavailability  or  by
irect  binding  of  thyroid  hormone  to  some  cellular  targets.
n  addition,  other  hormones  with  potent  vascular  effects
romote  acute  vasodilatation  by  non-genomic  mechanisms
r,  more  speciﬁcally,  by  stimulating  NO  formation  through
I3K/Akt  in  VSMCs.  Studies  have  identiﬁed  the  PI3K/Akt
ignalling  axis  as  an  oestrogen  transduction  component  in
ascular  smooth  muscle  cells:  oestrogen  opens  calcium-
ctivated  potassium  channels  in  human  coronary  artery
mooth  muscle  cells  by  stimulating  nNOS  via  a  transduction
equence  involving  PI3K  and  Akt  [28].
onclusions
he  results  of  these  studies  are  of  potential  clinical
elevance.  Endothelial  dysfunction,  resulting  from  a  reduc-
ion  in  NO  availability  and  LDL  oxidation,  is  a  common
vent  in  cardiovascular  disease,  and  thyroid  dysfunction
s  a  frequent  condition  that  confers  an  increased  risk  of
ardiovascular  complications.  It  may  be  envisaged  that  tri-
odothyronine  treatment  induces  increased  production  of
O,  which  is  associated  with  activation  of  the  PI3K/Akt  sig-
alling  pathway  and  increased  NOS  isoforms,  resulting  in  a
igniﬁcant  decrease  in  myosin  light  chain  phosphorylation
evels  and  decreased  vascular  response  to  contractile  stim-
li.
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